Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra and Zinc vs Prednisone in Severe Alcoholic Hepatitis
NCT04072822Phase 2
Key facts
- Status
- Completed
- Start
- Jul 2020
- Primary completion
- May 2022
- Countries
- 1
- Sponsor
- Indiana University
- Modality
- Cytokines & Interferons
- Drugs
- anakinra
- Conditions
- alcoholic hepatitis (AH)
01
Overview
Phase 2, randomised, double-blind trial of anakinra in alcoholic hepatitis (AH), sponsored by Indiana University. Started Jul 2020; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Registry description
This multicenter, randomized, double blinded, placebo-controlled clinical trial is focused on novel treatments for severe alcoholic hepatitis (AH), a life-threatening stage of alcoholic liver injury that has a short-term mortality rate much higher than that of other liver diseases.
The primary objective of the study is to determine the clinical efficacy and safety of Anakinra (plus zinc) compared to the current standard medical treatment consisting of prednisone in participants with clinically severe AH. Key secondary objectives broadly are as follows: (a) to evaluate the use of biomarkers…
Beyond the preview
Go deeper on NCT04072822.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04072822.